| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,873 | -5,767 |
| Depreciation | 151 | 103 |
| Stock-based compensation related to options granted to employees and directors | 1,377 | 1,220 |
| Change in operating lease liability | 79 | 68 |
| Decrease in other accounts receivable and prepaid expenses | 307 | 495 |
| Increase (decrease) in trade payables | 340 | -83 |
| Loss (gain) on change in fair value of warrants (note 4) | -179 | -179 |
| Increase (decrease) in other accounts payable and accrued expenses | 177 | - |
| Total net cash used in operating activities | -6,235 | -5,133 |
| Proceeds from issuance of shares in at-the-market (atm) offering (note 5) | 4,348 | 4,035 |
| Proceeds from short-term loans (note 7) | -199 | -199 |
| Debt-for-equity swap | -450 | -450 |
| Proceeds from warrants issuance (note 5) | 1,501 | 1,501 |
| Total net cash provided by financing activities | 6,100 | 5,787 |
| Decrease in cash, cash equivalents and restricted cash | -135 | 654 |
| Cash and cash equivalents at beginning of period | 371 | - |
| Cash and cash equivalents at end of period | 236 | - |
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)